Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Enquête sur la vue et l'audition sur les effets sur le délire (SHIELD)

27 octobre 2026 mis à jour par: Johns Hopkins University

Initiative prospective pour examiner et traiter la perte auditive, la perte de vision et le délire en milieu hospitalier

The goal of this observational study is to learn about sensory loss in hospital patients with delirium. The main questions it aims to answer are:

  • Are hearing and vision loss related to increased risk of having delirium?
  • Do hearing and vision loss contribute to more severe delirium?
  • Do sensory loss and/or delirium affect patient satisfaction with hospital care?

Participants will be asked to:

  • answer delirium screening questions,
  • undergo hearing & vision screenings, and
  • complete questionnaires about the hospital stay.

The second part of this study is a clinical trial. Researchers will compare different hospital units to see if changing communication affects the number of patients with delirium. The main questions it aims to answer are:

• Does sharing information about communication and/or providing hearing devices change the number of hospital patients with delirium?

Participants in the study will be asked to complete delirium screenings and answer questions about their hearing and communication.

Aperçu de l'étude

Description détaillée

This is a prospective cohort study entitled Sight & Hearing Investigation into Effects on Delirium (SHIELD), which aims of to characterize the impact of sensory impairment (i.e., vision and/or hearing loss) on inpatient delirium and experience. The initial phase of this research includes delirium, hearing, and vision screenings, as well as questionnaires regarding satisfaction with care, all of which are observational and do not constitute treatment or intervention. Researchers will conduct electronic medical record reviews to determine whether new patients have been admitted to the units of recruitment on a daily basis and collect relevant demographic and medical information. Eligible patients will be screened to with the 4AT identify delirium and the 3D-CAM-S to characterize delirium severity. After obtaining informed consent, patients will undergo bedside hearing and vision screenings, and complete patient satisfaction questionnaires.

Type d'étude

Observationnel

Inscription (Réel)

1312

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Maryland
      • Baltimore, Maryland, États-Unis, 21224
        • Johns Hopkins Bayview Medical Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

65 ans et plus (Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Participants over the age of 60 who was admitted to Bayview Medicine A, B, or C who meet inclusion criteria.

La description

Inclusion Criteria:

  • inpatient on Johns Hopkins Bayview Medicine A, Medicine B, or Carol Ball unit
  • communicates using speech and language
  • able to converse in English

Exclusion Criteria:

  • nonverbal
  • unable to communicate using English language
  • currently under airborne or droplet isolation precautions

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: ECOLOGIC_OR_COMMUNITY
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Delirium & Sensory Loss

The observational portion of the study, during which participants are screened for delirium. Consented individuals also complete bedside hearing and vision screenings, and provide information regarding care on patient satisfaction questionnaires.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Participants With Delirium as Assessed by 4AT Rapid Clinical Test for Delirium (4AT)
Délai: Approximately daily during hospitalization up to 6 months

Diagnosis of delirium using 4AT Rapid Clinical Test for Delirium (4AT). This test has a score range of 0 to 12, with a score of 4 or more indicating a positive delirium result. A score between 1 and 3 is indicative of possible cognitive impairment. Delirium symptom severity can be informally inferred from the test score, but the study will not be using the 4AT Rapid Clinical Test for Delirium (4AT) to measure delirium severity.

Approximately daily during hospitalization up to 6 months
Percentage of Participants With Delirium as Assessed by 4AT Rapid Clinical Test for Delirium in Proportion to Total Number of Patients Screened
Délai: Approximately daily during hospitalization up to 6 months

Counts of delirium diagnosed using 4AT Rapid Clinical Test for Delirium (4AT) score of 4 or greater, in comparison to the total number of patients screened.

The 4AT Rapid Clinical Test for Delirium (4AT) has a score range of 0 to 12, with a score of 4 or more indicating a positive delirium result. A score between 1 and 3 is indicative of possible cognitive impairment. Delirium symptom severity can be informally inferred from the test score, but the study will not be using the 4AT Rapid Clinical Test for Delirium (4AT) to measure delirium severity.

Approximately daily during hospitalization up to 6 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Severity of Delirium Quantified by the 3-Minute Diagnostic Interview for Confusion Assessment Method-Defined Delirium (3D-CAM)
Délai: Approximately daily during hospitalization up to 6 months

Study participants who score a 1 or higher on the 4AT Rapid Clinical Test for Delirium (4AT) over the duration of time inpatient on the three hospital units of recruitment (Johns Hopkins Bayview Medicine A, Medicine B, and Carol Ball units). Quantification of delirium severity from 3-Minute Diagnostic Interview for Confusion Assessment Method-Defined Delirium Severity (3D-CAM-S) score. The possible range of scores is from 0 to 20, with a higher number indicating the presence of more delirium signs and symptoms. However, the diagnosis of delirium using this metric depends on the presence of four characteristic features of delirium. Scores summed and averaged over the data collection period.

Approximately daily during hospitalization up to 6 months
Satisfaction With Care Assessed Using the Questionnaire on the Quality of Physician-Patient Interaction (QQPI)
Délai: Once during hospitalization up to 6 months

Self-reported satisfaction with hospital care from scores on Questionnaire on the Quality of Physician-Patient Interaction (QQPPI) and/or Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) measures.

Possible scores on the QQPPI range from 14 to 70; higher scores indicate higher patient satisfaction.

Once during hospitalization up to 6 months
Satisfaction With Care Assessed Using the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS)
Délai: Once during hospitalization up to 6 months

Self-reported satisfaction with hospital care from scores on Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) measures. Possible scores on the HCAHPS range from 11 to 62 regarding the hospital stay; between 0-4 on each of the two personal health questions; 0-10 for overall hospital rating. Higher scores are better.

Once during hospitalization up to 6 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Hearing Sensitivity as Quantified With Four-Frequency Pure Tone Average (PTA) for the Better-Hearing Ear
Délai: Once during hospitalization up to 6 months

Hearing sensitivity will be quantified based on the average of thresholds measured for four pure tone frequencies (500, 1000, 2000, and 4000 Hz). Thresholds will be measured under earphones during an iPad-based SHOEBOX audiometric screening. PTA values range from -20 to 90 decibels hearing level (dB HL). A higher pure tone average (PTA) suggests that higher signal intensities were necessary for the participant to hear and respond to the stimuli, which also suggests poorer hearing.

World Health Organization categories for PTA are include 25 or less: no impairment, 26 to 40: slight impairment, 41 to 60: moderate impairment, 61 to 80: severe impairment, and 81 or greater: profound impairment including deafness.

Once during hospitalization up to 6 months
Binocular Distance Visual Acuity Quantified With E-Book From National Health and Aging Trends Study (NHATS)
Délai: Once during hospitalization up to 6 months

Vision screenings will be performed using the National Health and Aging Trends Study (NHATS) Vision e-book developed by Ridgevue Vision on an iPad. Participants will not use glasses or contacts during the testing.

Distance visual acuity will be measured at 5 feet. Scores range from 50/20 to 4/20, with smaller numbers indicating better distance visual acuity.

Once during hospitalization up to 6 months
Binocular Contrast Sensitivity Quantified With E-Book From National Health and Aging Trends Study (NHATS)
Délai: Once during hospitalization up to 6 months

Vision screenings will be performed using the National Health and Aging Trends Study (NHATS) Vision e-book developed by Ridgevue Vision on an iPad. Participants will not use glasses or contacts during the testing.

Contrast sensitivity will also be measured at a distance of 5 feet. Scores for this test range from 0.5 to 2.0 with a larger score indicating better contrast sensitivity.

Once during hospitalization up to 6 months
Binocular Near Visual Acuity Quantified With E-Book From National Health and Aging Trends Study (NHATS)
Délai: Once during hospitalization up to 6 months

Vision screenings will be performed using the National Health and Aging Trends Study (NHATS) Vision e-book developed by Ridgevue Vision on an iPad. Participants will not use glasses or contacts during the testing.

Near visual acuity will be measured at usual reading distance. Scores for this test range from 32/20 to 2.5/20, with smaller numbers indicating better near visual acuity.

Once during hospitalization up to 6 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Nicholas S Reed, Au.D., Ph.D., Assistant Professor, Department of Epidemiology
  • Chercheur principal: Esther Oh, MD, Ph.D., Associate Professor, Departments of Medicine and Psychiatry

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

11 janvier 2023

Achèvement primaire (Réel)

15 décembre 2023

Achèvement de l'étude (Réel)

15 décembre 2023

Dates d'inscription aux études

Première soumission

7 décembre 2023

Première soumission répondant aux critères de contrôle qualité

7 décembre 2023

Première publication (Réel)

20 décembre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

27 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Limited data sets of information may be available to other researchers, pending approval of the Johns Hopkins Medicine Institutional Review Board.

For participants who have provided informed consent, this information includes demographics (age, sex, race), Charlson comorbidity index score, delirium screening and severity results, hearing screening results, vision screening results, and patient satisfaction data.

For patients who qualified for study inclusion under waivers of documentation of informed consent and HIPAA, this information includes demographics (age, sex, race) and delirium screening and severity results.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner